Jens J. Holst

Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2.

Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects.

Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.

Small-molecule agonists for the glucagon-like peptide 1 receptor.

Cecal infusion of butyrate increases intestinal cell proliferation in piglets.

Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.

Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats.

Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study.

G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction.

Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism.

Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion.

Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome.

Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed rats.

Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report.

The T-allele of TCF7L2 rs7903146 associates with a reduced compensation of insulin secretion for insulin resistance induced by 9 days of bed rest.

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.

Sex steroids affect triglyceride handling, glucose-dependent insulinotropic polypeptide, and insulin sensitivity: a 1-week randomized clinical trial in healthy young men.

Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure.

Delayed β-cell response and glucose intolerance in young women with Turner syndrome.

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.

Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes.

Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome.

Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test.

The effect of PCSK1 variants on waist, waist-hip ratio and glucose metabolism is modified by sex and glucose tolerance status.

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.

Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs.

The effect of glucagon-like peptide 1 on cardiovascular risk.

Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.

GPR119 as a fat sensor.

The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on β-cells.

Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations.

Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.

Effects of pre-meal drinks with protein and amino acids on glycemic and metabolic responses at a subsequent composite meal.

The glycemic, insulinemic and plasma amino acid responses to equi-carbohydrate milk meals, a pilot- study of bovine and human milk.

A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin.

Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.

Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease.

GLP-2 delays but does not prevent the onset of necrotizing enterocolitis in preterm pigs.

Removal of duodenum elicits GLP-1 secretion.

Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety.

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty.

Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.

Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.

Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty.

Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients.

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.

Effect of dietary advanced glycation end products on postprandial appetite, inflammation, and endothelial activation in healthy overweight individuals.

Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes.

Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.

Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease.

A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients.

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial.

Insulin resistance alters islet morphology in nondiabetic humans.

GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle.

Reduction in cardiovascular risk factors and insulin dose, but no beta-cell regeneration 1 year after Roux-en-Y gastric bypass in an obese patient with type 1 diabetes: a case report.

KCNQ1 long QT syndrome patients have hyperinsulinemia and symptomatic hypoglycemia.

Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs.

The authors reply.

Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition.

Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans.

Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery.

Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.

Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease.

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls.

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals.

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report.

Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.

Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.

Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.

Mechanisms behind the superior effects of interval vs continuous training on glycaemic control in individuals with type 2 diabetes: a randomised controlled trial.

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.

Molecular mechanisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine.

A single supplement of a standardised bilberry (Vaccinium myrtillus L.) extract (36 % wet weight anthocyanins) modifies glycaemic response in individuals with type 2 diabetes controlled by diet and lifestyle.

Effects of hydrolysed casein, intact casein and intact whey protein on energy expenditure and appetite regulation: a randomised, controlled, cross-over study.

GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgery.

Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes.

Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients.

Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study.

The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo.

Hypoglycemia-associated changes in the electroencephalogram in patients with type 1 diabetes and normal hypoglycemia awareness or unawareness.

Incretin effect after oral amino acid ingestion in humans.

Stability of glucagon-like peptide 1 and glucagon in human plasma.

Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients.

Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass.

Patients with psoriasis are insulin resistant.

Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow.

Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men.

The effects of TNF-α on GLP-1-stimulated plasma glucose kinetics.

Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance.

The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine.

Incretin and glucagon levels in adult offspring exposed to maternal diabetes in pregnancy.

L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients.

Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study.

Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis.

Bile acid mediated effects on gut integrity and performance of early-weaned piglets.

GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.

Important species differences regarding lymph contribution to gut hormone responses.

Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept.

The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1.

Early gradual feeding with bovine colostrum improves gut function and NEC resistance relative to infant formula in preterm pigs.

The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans.

Transcriptional and Functional Characterization of the G Protein-Coupled Receptor Repertoire of Gastric Somatostatin Cells.

Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes.

Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation.

Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass.

Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors.

Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.

Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of Metabolism.

GLP1- and GIP-producing cells rarely overlap and differ by bombesin receptor-2 expression and responsiveness.

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.

Cephalic phase secretion of insulin and other enteropancreatic hormones in humans.

Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes.

Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism.

Effects of Gastric Bypass and Gastric Banding on Bone Remodeling in Obese Patients With Type 2 Diabetes.

Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.

The regulation of function, growth and survival of GLP-1-producing L-cells.

Evidence of Extrapancreatic Glucagon Secretion in Man.

Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides.

Jejunal feeding is followed by a greater rise in plasma cholecystokinin, peptide YY, glucagon-like peptide 1, and glucagon-like peptide 2 concentrations compared with gastric feeding in vivo in humans: a randomized trial.

Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.

The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs.

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion.

Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men.

GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes.

Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy.

Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36.

A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.

No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3 Years After Gastric Bypass Surgery.

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.

Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes.

Use of anesthesia dramatically alters the oral glucose tolerance and insulin secretion in C57Bl/6 mice.

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.

Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota.

Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma.

Guidelines: Surgical or medical therapy for patients with obesity and T2DM?

Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets.

Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial.

Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men.

Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion.

Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery.

The biology of glucagon and the consequences of hyperglucagonemia.

Serum lipase activity and concentration during intravenous infusions of GLP-1 and PYY3-36 and after ad libitum meal ingestion in overweight men.

The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes.

Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.

Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.

Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference.

Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.

Gut: A key player in the pathogenesis of type 2 diabetes?

Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation.

Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes.

Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.

Proteomics reveals the effects of sustained weight loss on the human plasma proteome.

Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response.

Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis.

Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men.

Variable reliability of surrogate measures of insulin sensitivity after Roux-en-Y gastric bypass.

Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass.

A safety and pharmacokinetic dosing study of glucagon-like peptide 2 in infants with intestinal failure.

Patients With Long-QT Syndrome Caused by Impaired -Encoded K11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia.

Acute effects of glucagon-like peptide-1, GLP-1, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers.

Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect.

Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose.

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers.

Glycaemic control and weight loss with semaglutide in type 2 diabetes.

Supplementation of Diet With Galacto-oligosaccharides Increases Bifidobacteria, but Not Insulin Sensitivity, in Obese Prediabetic Individuals.

Glucose ingestion causes cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects.

A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite.

Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion.

Interdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral Nutrition.

Role of Glucagon in Catabolism and Muscle Wasting of Critical Illness and Modulation by Nutrition.

Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial.

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice.

Health care professionals from developing countries report educational benefits after an online diabetes course.

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.

Why is it so difficult to measure glucagon-like peptide-1 in a mouse?

Effects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in rats.

Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals.

The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes.

Addition of Rye Bran and Pea Fiber to Pork Meatballs Enhances Subjective Satiety in Healthy Men, but Does Not Change Glycemic or Hormonal Responses: A Randomized Crossover Meal Test Study.

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass.

Pancreatic Polypeptide in Parkinson's Disease: A Potential Marker of Parasympathetic Denervation.

Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.

Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes.

GIP(3-30)NH is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.

Enteroendocrine K and L cells in healthy and type 2 diabetic individuals.

Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.

Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition.

Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis.

Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues.

Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia.

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production.

TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?

On the relationship between glucose absorption and glucose-stimulated secretion of GLP-1, neurotensin, and PYY from different intestinal segments in the rat.

Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.

Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial.

Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes.

Pre-Meal Effect of Whey Proteins on Metabolic Parameters in Subjects with and without Type 2 Diabetes: A Randomized, Crossover Trial.

Oxyntomodulin: Actions and role in diabetes.

Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery.

Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer.

The glucagon like peptide-2 'axis': Capacity for production and response following intestinal resection or repair of gastroschisis in infants.

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses.

Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers.

Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas.

Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release.

The effect of casein, hydrolyzed casein, and whey proteins on urinary and postprandial plasma metabolites in overweight and moderately obese human subjects.

Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up.

Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss.

Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb.

Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.

Inhibiting RHOA Signaling in Mice Increases Glucose Tolerance and Numbers of Enteroendocrine and Other Secretory Cells in the Intestine.

The prebiotic inulin improves substrate metabolism and promotes short-chain fatty acid production in overweight to obese men.

Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice.

Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men.

Glucose Tolerance Tests and Osteocalcin Responses in Healthy People.

Renoprotective effects of dulaglutide in patients with T2DM and CKD.

No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course.

Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects.

Reduced GLP-1 Secretion at 30 Minutes After a 75-g Oral Glucose Load Is Observed in Gestational Diabetes Mellitus: A Prospective Cohort Study.

Gastrointestinal motility, gut hormone secretion, and energy intake after oral loads of free fatty acid or triglyceride in older and middle-aged men.

Mechanisms Preserving Insulin Action during High Dietary Fat Intake.

Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects.

Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs.

Neuromedin U Does Not Act as a Decretin in Rats.

Abscisic acid stimulates the release of insulin and of GLP-1 in the rat perfused pancreas and intestine.

The aromatic amino acid sensor GPR142 controls metabolism through balanced regulation of pancreatic and gut hormones.

Glucose homeostasis in statin users-The LIFESTAT study.

Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Energy intake, gastrointestinal transit, and gut hormone release in response to oral triglycerides and fatty acids in men with and without severe obesity.

Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery.

Biliopancreatic diversion with duodenal switch (BPD-DS) and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) result in distinct post-prandial hormone profiles.

The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial.

Effects of active commuting and leisure-time exercise on appetite in individuals with overweight and obesity.

Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery.

Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals.

Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study.

Gastrointestinal motility in patients with end-stage renal disease on chronic hemodialysis.

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.

Postprandial Nutrient Handling and Gastrointestinal Secretion of Hormones After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy.

Bile acids drive colonic secretion of glucagon-like-peptide 1 and peptide-YY in rodents.